Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry

• References

• 1 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
• 2 Greengard JS, Sun X, Xu X. et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362.
• 3 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
• 4 Deguchi H, Pecheniuk NM, Elias DJ. et al. Highdensity lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
• 5 Saposnik B, Reny JL, Gaussem P. et al. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103: 1311-1318.
• 6 Medina P, Navarro S, Estelles A. et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 2004; 91: 905-911.
• 7 Arnaud E, Nicaud V, Poirier O. et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 2000; 20: 585-592.
• 8 Hoppe B, Tolou F, Radtke H. et al. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005; 105: 1549-1551.
• 9 Yamazaki T, Sugiura I, Matsushita T. et al. A phenotypically neutral dimorphism of protein S: The substitution of Lys155 by Glu in the second EGF domain predicted by an A to G base exchange in the gene. Thromb Res 1993; 70: 395-403.
• 10 Hayashi T, Nishioka J, Shigekiyo T. et al. Protein S Tokushima: Abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factorlike domain of protein S. Blood 1994; 83: 683-690.
• 11 Fukodome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-26491.
• 12 Stearns-Kurosawa DJ, Kurosawa S, Mollica JS. et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-10216.
• 13 Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
• 14 Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997; 100: 411-418.
• 15 Liaw PC, Neuenschwander PR, Smirnov MD. et al. Mechanisms by which soluble endothelial protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000; 277: 24851-24854.
• 16 Uitte de Willige S, van Marion V, Rosendaal FR. et al. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost 2004; 2: 1305-1310.
• 17 Medina P, Navarro S, Estelles A. et al. Polymorphisms in the endothelial protein C receptor gene and thrombophilia. Thromb Haemost 2007; 98: 564-569.
• 18 Römisch J, Feussner A, Vermohlen S. et al. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coag Fibrinolysis 1999; 10: 471-479.
• 19 Römisch J, Vermohlen S. Feussner et al. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999; 29: 292-299.
• 20 Roemisch J, Feussner A, Nerlich C. et al. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coag Fibrinolysis 2002; 13: 433-441.
• 21 van Minkelen R, de Visser MC, Vos HL. et al. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005; 105: 4898.
• 22 Weisbach V, Ruppel R, Eckstein R. The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism. Thromb Haemost 2007; 97: 870-872.
• 23 Xu X, Bauer KA, Griffin JH. Two multiplex PCRbased DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. Thromb Res 1999; 93: 265-269.
• 24 Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Controlled Clin Trials 1997; 18: 274.
• 25 Hoppe B, Heymann GA, Radtke H. et al. Association of Marburg I polymorphism of factor VII-activating protease with venous thromboembolism is limited to idiopathic events. Blood 2005; 105: 4899.
• 26 Kimura R, Honda S, Kawasaki T. et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese subjects. Blood 2006; 107: 1737-1738.